Personalized Intervention Program: Tobacco Treatment for Patients at Risk for Lung Cancer (PIP)
The purpose of this study is to test the efficacy of two separate, sequential interventions to promote tobacco cessation/reduction in patients who are screened for lung cancer or are eligible for lung cancer screening. Each intervention will be compared to standard of care. The first intervention will be a personalized message intervention, the second intervention will consist of a biofeedback-based intervention.
Checked against the public recordLast updated Apr 21, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Prevention
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Yale University
- Interventions being studied
- Behavioral: personalized cessation care; Behavioral: bio feedback; Other: standard care
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Current Smoker. * 20 pack per year smoking history. * Eligible for the Smilow treatment program. * Willing to enroll in smoking cessation program. * Willing to be randomized in smoking cessation study. * English speaking. Exclusion Criteria: * Dementia or current serious psychiatric or unstable medical illness. * Pregnancy or breast feeding. * Known fat malabsorption diseases that may affect skin carotenoid status.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Yale UniversityNew Haven, Connecticut
- Medical University of South Carolina: Hollings Cancer CenterCharleston, South Carolina
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 21, 2023. Always confirm current availability with the study team.